Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]

Table 3 Prevalence of various components of the metabolic syndrome among the 9795 randomized participants in the FIELD study

Metabolic syndrome feature: ATPIII criteria *	Men (n= 6138)		Women (n= 3657)		Total (n= 9795)
Metabolic syndrome feature: ATPIII criteria *	n	%	n	%	n	%
Waist measurement (women >88 cm; men >102 cm)	3613	58.9	3034	83.0	6647	67.9
Triglycerides >= 1.7 mmol/L	3073	50.1	2020	55.2	5093	52.0
HDL (men <40 mg/dL; women <50 mg/dL)	3365	54.8	2455	67.1	5820	59.4
Hypertension (SBP >= 130 and DBP >= 85 mm Hg)	5050	82.3	3131	85.6	8181	83.5
Fasting glucose >= 110 mg/dL or diabetes	6133	99.9	3646	99.7	9779	99.8

* When 3 of the 5 listed characteristics are present, a diagnosis of metabolic syndrome is established (84% of the cohort met the criteria)

ISSN: 1475-2840